A β-blocker drug slows the progression of artery-clogging plaque in the carotid arteries of healthy people, researchers report in the April 2 issue of Circulation: Journal of the American Heart Association.
The 3-year study by researchers from Sweden found that low dosages (25 mg once daily) of metoprolol CR/XL slows the rate of progression of atherosclerosis by 40% in healthy, symptom-free people who have plaque buildup in their carotid arteries.
The Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) is a randomized, double-blind, placebo-controlled trial. Study participants were 793 urban, white Swedish people participating in the Malmo Diet and Cancer Study. Participants were randomly assigned to one of four groups: metoprolol CR/XL, fluvastatin, a combination of metoprolol CR/XL and fluvastatin, and placebo. Participants were enrolled beginning in November 1994 for 36-month treatment periods; the study ended in February 1999. The researchers measured the progression of artery wall thickening at 18 months and 36 months.
Mitka M. β-Blocker Benefit. JAMA. 2001;285(16):2070. doi:10.1001/jama.285.16.2070-JQU10003-4-1
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.